image stringlengths 20 66 | question stringclasses 16
values | answer stringlengths 3 10.7k |
|---|---|---|
PMC9413033_molecules-27-05053-f005_385005.jpg | What is the main focus of this visual representation? | SEM images of M-P-S materials synthesized from metal halides and (P2S5 + P) at 500 °C. The right images are higher magnification images of the products shown in the left images. |
PMC9413033_molecules-27-05053-f005_385006.jpg | What is the focal point of this photograph? | SEM images of M-P-S materials synthesized from metal halides and (P2S5 + P) at 500 °C. The right images are higher magnification images of the products shown in the left images. |
PMC9413033_molecules-27-05053-f005_385003.jpg | What is the principal component of this image? | SEM images of M-P-S materials synthesized from metal halides and (P2S5 + P) at 500 °C. The right images are higher magnification images of the products shown in the left images. |
PMC9413033_molecules-27-05053-f005_385001.jpg | What's the most prominent thing you notice in this picture? | SEM images of M-P-S materials synthesized from metal halides and (P2S5 + P) at 500 °C. The right images are higher magnification images of the products shown in the left images. |
PMC9413034_pharmaceutics-14-01559-f003_385010.jpg | What's the most prominent thing you notice in this picture? | SEM images and diameter distributions of nanofibrous samples produced by nozzle-free electrospinning. The scale bar is 10 µm on every microscopic image. (A1) In the case of the nanofibers containing 5 w% ciprofloxacin (NF-5), the free-surface electrospinning was successful. The average fiber diameter was 1167 ± 415 nm,... |
PMC9413034_pharmaceutics-14-01559-f003_385009.jpg | What stands out most in this visual? | SEM images and diameter distributions of nanofibrous samples produced by nozzle-free electrospinning. The scale bar is 10 µm on every microscopic image. (A1) In the case of the nanofibers containing 5 w% ciprofloxacin (NF-5), the free-surface electrospinning was successful. The average fiber diameter was 1167 ± 415 nm,... |
PMC9413034_pharmaceutics-14-01559-f003_385012.jpg | What is the focal point of this photograph? | SEM images and diameter distributions of nanofibrous samples produced by nozzle-free electrospinning. The scale bar is 10 µm on every microscopic image. (A1) In the case of the nanofibers containing 5 w% ciprofloxacin (NF-5), the free-surface electrospinning was successful. The average fiber diameter was 1167 ± 415 nm,... |
PMC9413034_pharmaceutics-14-01559-f008_385018.jpg | What is being portrayed in this visual content? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385024.jpg | What is the central feature of this picture? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385015.jpg | What key item or scene is captured in this photo? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385022.jpg | What is being portrayed in this visual content? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385019.jpg | What stands out most in this visual? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385014.jpg | What is the focal point of this photograph? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385016.jpg | What is being portrayed in this visual content? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385026.jpg | What is the focal point of this photograph? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385020.jpg | What key item or scene is captured in this photo? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385023.jpg | What is being portrayed in this visual content? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413034_pharmaceutics-14-01559-f008_385013.jpg | What is being portrayed in this visual content? | SEM images of the ciprofloxacin-loaded nanofibers taken during the 26-month stability study. The morphology of the nozzle-free nanofiber sample (NF-5) remained stable over the 26 months. For the nanofibers produced using a nozzle (SN-10 and SN-5), aging of the structure was observed at 16 and 26 months. The scale bar i... |
PMC9413064_sensors-22-06258-f0A14_385031.jpg | What is the dominant medical problem in this image? | (A–H) shows the detection results of eight algorithms PSTNN, TV-PCP, VNTFR, anisotropy, ASTTV, SRWS, RPCA and propose method, respectively, under sequence H. |
PMC9413064_sensors-22-06258-f0A14_385034.jpg | What does this image primarily show? | (A–H) shows the detection results of eight algorithms PSTNN, TV-PCP, VNTFR, anisotropy, ASTTV, SRWS, RPCA and propose method, respectively, under sequence H. |
PMC9413064_sensors-22-06258-f0A14_385029.jpg | What is the principal component of this image? | (A–H) shows the detection results of eight algorithms PSTNN, TV-PCP, VNTFR, anisotropy, ASTTV, SRWS, RPCA and propose method, respectively, under sequence H. |
PMC9413064_sensors-22-06258-f0A14_385028.jpg | What's the most prominent thing you notice in this picture? | (A–H) shows the detection results of eight algorithms PSTNN, TV-PCP, VNTFR, anisotropy, ASTTV, SRWS, RPCA and propose method, respectively, under sequence H. |
PMC9413094_nanomaterials-12-02760-f002_385036.jpg | What is the focal point of this photograph? | (a) The X-ray diffraction patterns of CNP (blue), CNP@Au1 (black) and CNP@Au2 (red), in which the main diffraction peaks of the maghemite (m) phase are indicated by the red pattern (30.3° (220), 35.6° (311), 43.3° (400), 53.7° (422), 57.3° (511), 62.9° (440) and 74.5° (533)) and the main diffraction peaks of the metall... |
PMC9413094_nanomaterials-12-02760-f002_385040.jpg | Can you identify the primary element in this image? | (a) The X-ray diffraction patterns of CNP (blue), CNP@Au1 (black) and CNP@Au2 (red), in which the main diffraction peaks of the maghemite (m) phase are indicated by the red pattern (30.3° (220), 35.6° (311), 43.3° (400), 53.7° (422), 57.3° (511), 62.9° (440) and 74.5° (533)) and the main diffraction peaks of the metall... |
PMC9413097_metabolites-12-00715-f006_385045.jpg | What is the main focus of this visual representation? | SEM micrographs of the EPSR4 at different magnifications, ×4000 (a), ×5000 (b), ×10,000 (c), ×15,000 (d), and the particle size distribution (e). |
PMC9413097_metabolites-12-00715-f006_385046.jpg | What is the focal point of this photograph? | SEM micrographs of the EPSR4 at different magnifications, ×4000 (a), ×5000 (b), ×10,000 (c), ×15,000 (d), and the particle size distribution (e). |
PMC9413097_metabolites-12-00715-f006_385043.jpg | What's the most prominent thing you notice in this picture? | SEM micrographs of the EPSR4 at different magnifications, ×4000 (a), ×5000 (b), ×10,000 (c), ×15,000 (d), and the particle size distribution (e). |
PMC9413097_metabolites-12-00715-f006_385044.jpg | What is shown in this image? | SEM micrographs of the EPSR4 at different magnifications, ×4000 (a), ×5000 (b), ×10,000 (c), ×15,000 (d), and the particle size distribution (e). |
PMC9413105_vaccines-10-01208-f006_385060.jpg | What key item or scene is captured in this photo? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385055.jpg | What can you see in this picture? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385058.jpg | What is the core subject represented in this visual? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385048.jpg | What's the most prominent thing you notice in this picture? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385054.jpg | Can you identify the primary element in this image? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385056.jpg | What is the core subject represented in this visual? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385049.jpg | What key item or scene is captured in this photo? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385059.jpg | What object or scene is depicted here? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385062.jpg | What is the focal point of this photograph? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385063.jpg | What's the most prominent thing you notice in this picture? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385053.jpg | What object or scene is depicted here? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385050.jpg | What is the principal component of this image? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413105_vaccines-10-01208-f006_385051.jpg | What is the dominant medical problem in this image? | The results of the histopathological examinations for pathological changes in (A) spleen, (B) lymph nodes and groin and (C) local administration. H&E, 100×. |
PMC9413108_molecules-27-05073-f005_385069.jpg | Describe the main subject of this image. | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on intestinal histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal villi from the muc... |
PMC9413108_molecules-27-05073-f005_385067.jpg | What is the central feature of this picture? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on intestinal histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal villi from the muc... |
PMC9413108_molecules-27-05073-f005_385070.jpg | What is being portrayed in this visual content? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on intestinal histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal villi from the muc... |
PMC9413108_molecules-27-05073-f005_385066.jpg | What can you see in this picture? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on intestinal histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal villi from the muc... |
PMC9413108_molecules-27-05073-f006_385078.jpg | What is the main focus of this visual representation? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f006_385074.jpg | What is being portrayed in this visual content? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f006_385072.jpg | Can you identify the primary element in this image? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f006_385075.jpg | What object or scene is depicted here? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f006_385076.jpg | What is the principal component of this image? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f006_385073.jpg | Can you identify the primary element in this image? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f006_385079.jpg | What object or scene is depicted here? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on hepatic histoarchitecture. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus. The sham-operated animals showed normal central venules (whit... |
PMC9413108_molecules-27-05073-f009_385064.jpg | What is the core subject represented in this visual? | Effect of intestinal ischemia/reperfusion (I/R) and methanolic Phyllanthus amarus leaf extract on intestinal Bax expression. IIRI: intestinal ischemia/reperfusion injury, FEB: febuxostat, LDPA: low-dose Phyllanthus amarus, HDPA: high-dose Phyllanthus amarus, a p < 0.05 versus sham, b p < 0.05 versus IIRI, c p < 0.05 ve... |
PMC9413128_pharmaceutics-14-01568-f0A1_385080.jpg | What can you see in this picture? | Visual representation of 3D-printed tablets from experiments M20 (high strength), M23 (medium strength), and M26 (low strength) with the 20% ethanol-water mixture. As can be discerned, an excess of material at tablet edges is observed for experiment M20, while experiment M26 yielded poorly bonded tablets due to high la... |
PMC9413134_sensors-22-06223-f001_385083.jpg | What stands out most in this visual? | Partially treated sample of the metal surface by treating to increase the contact area of the base materials for spraying before “shot blasting”. |
PMC9413136_micromachines-13-01291-f009_385087.jpg | What is the main focus of this visual representation? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413136_micromachines-13-01291-f009_385086.jpg | What is shown in this image? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413136_micromachines-13-01291-f009_385084.jpg | What is the central feature of this picture? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413136_micromachines-13-01291-f009_385091.jpg | What is shown in this image? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413136_micromachines-13-01291-f009_385088.jpg | What is the core subject represented in this visual? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413136_micromachines-13-01291-f009_385090.jpg | What does this image primarily show? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413136_micromachines-13-01291-f009_385085.jpg | What stands out most in this visual? | The bottom surface topography of deep trenches machined using different hatch spacings of (a1) 5 μm, (b1) 10 μm, (c1) 15 μm and (d1) 30 μm and their enlarged views of (a2–d2) at the average laser power of 2.169 W and the scanning speed of 1000 mm/s. |
PMC9413140_F7_385094.jpg | What is the core subject represented in this visual? | Effect of BDE-47 administration on mammary tumor development in the C3(1)/TAg model. Mean ± SEM and individual data points for (A) total volume of tumors and (B) total weight of tumors. Representative 10 mm 2D coronal slices, in maximum intensity projection (mip), from 3D PET/CT images of mice randomized to (C) only ve... |
PMC9413140_F7_385093.jpg | What is shown in this image? | Effect of BDE-47 administration on mammary tumor development in the C3(1)/TAg model. Mean ± SEM and individual data points for (A) total volume of tumors and (B) total weight of tumors. Representative 10 mm 2D coronal slices, in maximum intensity projection (mip), from 3D PET/CT images of mice randomized to (C) only ve... |
PMC9413194_f2_385096.jpg | What is the main focus of this visual representation? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385100.jpg | What stands out most in this visual? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385103.jpg | What is the central feature of this picture? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385102.jpg | What is the central feature of this picture? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385098.jpg | What is the dominant medical problem in this image? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385101.jpg | What is the central feature of this picture? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385104.jpg | What's the most prominent thing you notice in this picture? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413194_f2_385105.jpg | What can you see in this picture? | A typical case. Enhanced CT (A), intraoperative DSA (B), and DSA 3D reconstruction (C) focusing on liver metastases before CSM-TACE. DSA focusing on liver metastases after CSM-TACE (D). Enhanced CT focusing on liver metastases 1 month after the third round of CSM-TACE (E). Simulation plan before 125I brachytherapy (F).... |
PMC9413228_F1_385108.jpg | What is the central feature of this picture? | A pictorial description of Cymbidium ensifolium leaf coloration. (A) leaf color alteration pertaining to development. (B) leaf color variation in mature C. ensifolium leaves depicting yellow, purple, and green coloration. |
PMC9413228_F1_385106.jpg | Can you identify the primary element in this image? | A pictorial description of Cymbidium ensifolium leaf coloration. (A) leaf color alteration pertaining to development. (B) leaf color variation in mature C. ensifolium leaves depicting yellow, purple, and green coloration. |
PMC9413228_F1_385107.jpg | Describe the main subject of this image. | A pictorial description of Cymbidium ensifolium leaf coloration. (A) leaf color alteration pertaining to development. (B) leaf color variation in mature C. ensifolium leaves depicting yellow, purple, and green coloration. |
PMC9413236_tomography-08-00166-f001_385109.jpg | Can you identify the primary element in this image? | A comparison of two cases of patients with frontal lobe meningioma with an asymptomatic onset that, on MRI images, document entirely different volumes of edema. In the first case, T1-weighted with MDC (A), T2-weighted (B), and FLAIR (C) images show a 2 cm para-alpine lesion with edema involving the entire frontal lobe.... |
PMC9413236_tomography-08-00166-f001_385112.jpg | What is shown in this image? | A comparison of two cases of patients with frontal lobe meningioma with an asymptomatic onset that, on MRI images, document entirely different volumes of edema. In the first case, T1-weighted with MDC (A), T2-weighted (B), and FLAIR (C) images show a 2 cm para-alpine lesion with edema involving the entire frontal lobe.... |
PMC9413236_tomography-08-00166-f001_385114.jpg | What can you see in this picture? | A comparison of two cases of patients with frontal lobe meningioma with an asymptomatic onset that, on MRI images, document entirely different volumes of edema. In the first case, T1-weighted with MDC (A), T2-weighted (B), and FLAIR (C) images show a 2 cm para-alpine lesion with edema involving the entire frontal lobe.... |
PMC9413236_tomography-08-00166-f001_385113.jpg | What is the focal point of this photograph? | A comparison of two cases of patients with frontal lobe meningioma with an asymptomatic onset that, on MRI images, document entirely different volumes of edema. In the first case, T1-weighted with MDC (A), T2-weighted (B), and FLAIR (C) images show a 2 cm para-alpine lesion with edema involving the entire frontal lobe.... |
PMC9413259_nutrients-14-03359-f002_385116.jpg | What can you see in this picture? | Dermoscopic findings in different types of BCC. (A) Milky-pink color structureless areas (*1), pink homogeneous areas (*2), short thin telangiectasia (*3), and erosion (*4) on the central part of the tumor in the case of superficial BCC. (B) A translucent nodule (*1) raised above the skin and arborizing vessels (*2) in... |
PMC9413259_nutrients-14-03359-f002_385115.jpg | Can you identify the primary element in this image? | Dermoscopic findings in different types of BCC. (A) Milky-pink color structureless areas (*1), pink homogeneous areas (*2), short thin telangiectasia (*3), and erosion (*4) on the central part of the tumor in the case of superficial BCC. (B) A translucent nodule (*1) raised above the skin and arborizing vessels (*2) in... |
PMC9413259_nutrients-14-03359-f002_385117.jpg | What is the main focus of this visual representation? | Dermoscopic findings in different types of BCC. (A) Milky-pink color structureless areas (*1), pink homogeneous areas (*2), short thin telangiectasia (*3), and erosion (*4) on the central part of the tumor in the case of superficial BCC. (B) A translucent nodule (*1) raised above the skin and arborizing vessels (*2) in... |
PMC9413259_nutrients-14-03359-f002_385118.jpg | Describe the main subject of this image. | Dermoscopic findings in different types of BCC. (A) Milky-pink color structureless areas (*1), pink homogeneous areas (*2), short thin telangiectasia (*3), and erosion (*4) on the central part of the tumor in the case of superficial BCC. (B) A translucent nodule (*1) raised above the skin and arborizing vessels (*2) in... |
PMC9413259_nutrients-14-03359-f008_385123.jpg | What is the dominant medical problem in this image? | Assessment of cutaneous DBP and SHH expression in low risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D) and anti-SHH (B,E) antibodies and recognized by the presence of brown reaction products found in the BCC samples. Scal... |
PMC9413259_nutrients-14-03359-f008_385120.jpg | Can you identify the primary element in this image? | Assessment of cutaneous DBP and SHH expression in low risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D) and anti-SHH (B,E) antibodies and recognized by the presence of brown reaction products found in the BCC samples. Scal... |
PMC9413259_nutrients-14-03359-f008_385121.jpg | What is shown in this image? | Assessment of cutaneous DBP and SHH expression in low risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D) and anti-SHH (B,E) antibodies and recognized by the presence of brown reaction products found in the BCC samples. Scal... |
PMC9413259_nutrients-14-03359-f009_385128.jpg | What's the most prominent thing you notice in this picture? | Assessment of cutaneous DBP and SHH expression in high risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D,G) and anti-SHH (B,E,H) antibodies and recognized by the presence of brown reaction products found in the BCC samples.... |
PMC9413259_nutrients-14-03359-f009_385131.jpg | What is the focal point of this photograph? | Assessment of cutaneous DBP and SHH expression in high risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D,G) and anti-SHH (B,E,H) antibodies and recognized by the presence of brown reaction products found in the BCC samples.... |
PMC9413259_nutrients-14-03359-f009_385133.jpg | What's the most prominent thing you notice in this picture? | Assessment of cutaneous DBP and SHH expression in high risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D,G) and anti-SHH (B,E,H) antibodies and recognized by the presence of brown reaction products found in the BCC samples.... |
PMC9413259_nutrients-14-03359-f009_385130.jpg | What can you see in this picture? | Assessment of cutaneous DBP and SHH expression in high risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D,G) and anti-SHH (B,E,H) antibodies and recognized by the presence of brown reaction products found in the BCC samples.... |
PMC9413259_nutrients-14-03359-f009_385135.jpg | What is the main focus of this visual representation? | Assessment of cutaneous DBP and SHH expression in high risk BCCs by the use of IHC. Representative images demonstrating cutaneous structures (tumoral (⁎) and stromal (□)) decorated by the anti-DBP (A,D,G) and anti-SHH (B,E,H) antibodies and recognized by the presence of brown reaction products found in the BCC samples.... |
PMC9413260_medicina-58-01011-f005_385125.jpg | Describe the main subject of this image. | Pulmonary CTA, 3D reconstructions. |
PMC9413264_polymers-14-03382-f003_385139.jpg | What is the focal point of this photograph? | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413264_polymers-14-03382-f003_385141.jpg | What is the focal point of this photograph? | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413264_polymers-14-03382-f003_385138.jpg | What is the core subject represented in this visual? | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413264_polymers-14-03382-f003_385148.jpg | What is the central feature of this picture? | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413264_polymers-14-03382-f003_385146.jpg | What does this image primarily show? | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413264_polymers-14-03382-f003_385137.jpg | What's the most prominent thing you notice in this picture? | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413264_polymers-14-03382-f003_385145.jpg | Describe the main subject of this image. | The scanning electron microscopy (SEM) images of PI film with (a) metallic Cu, (b,c) Cu2−xS NPs, and (d–f) the corresponding energy−dispersive X−ray spectrometry (EDXS) mapping results. (g,h) The transmission electron microscopy (TEM) images of Cu2−xS derived from PI with different magnifications, and (i) the correspon... |
PMC9413267_polymers-14-03368-f003_385150.jpg | What is the focal point of this photograph? | Photographs of SEM and cryo-SEM. (A) SEM examination of TMZ crystal micromorphology and micro-TMZ micromorphology. (B) Cryo-SEM analysis of 20 wt% PLGA–PEG–PLGA blend samples demonstrates the creation of a distinctive hydrogel mesh structure at 37 °C. (C) Three micro-TMZ distribution topologies were identified in the t... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.